CytoMed Therapeutics (NASDAQ:GDTC) Trading Up 1% – Here’s What Happened

Shares of CytoMed Therapeutics Limited (NASDAQ:GDTC) traded up 1% during trading on Thursday . The company traded as high as $0.98 and last traded at $0.98. Approximately 7,126 shares traded hands during mid-day trading, a decline of 47% from the average session volume of 13,461 shares. The stock had previously closed at $0.9699.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CytoMed Therapeutics in a research report on Wednesday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

CytoMed Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.06, a current ratio of 5.17 and a quick ratio of 5.17. The business has a fifty day simple moving average of $1.05 and a two-hundred day simple moving average of $1.07.

Insider Activity at CytoMed Therapeutics

In other CytoMed Therapeutics news, Director Chee Kong Choo acquired 112,000 shares of the stock in a transaction dated Wednesday, May 13th. The shares were purchased at an average price of $1.15 per share, for a total transaction of $128,800.00. Following the purchase, the director directly owned 430,324 shares of the company’s stock, valued at approximately $494,872.60. This trade represents a 35.18% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.